For different subtypes of lung cancer, high expression of BCL2L1 correlates with reduced survival of LA patients (HR (95%CI) = 1.67(1.29~2.15)), but it did not affect survival time of patients with LSC (HR (95%CI) =0.79(0.62~1.02)). This evidence concerns the gene BCL2L1 and lung carcinoma.